Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
When Innovation Outpaces HTA, Access Struggles to Keep Up
Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
Doubling Down On Innovation, Recovery
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
Developing a Product Launch Strategy for an Orphan Drug
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Investing for Success: Finding the Right Launch Balance
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Rethinking Obesity: Wegovy
New drug aims to turn obesity into treatable chronic condition.
Fear Factor: Palforzia
Peanut allergies raise fears among parents, teachers, but treatment is now available.
Formidable Option: Orgovyx
Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.
No Small Feat: Nurtec ODT
The aggressive strategy behind a small company’s quick ascent in migraine market.
‘Rare’ Reinforcement: Evrysdi
Latest disease-modifying market entrant for SMA addresses administration, access gaps.
New Heights: Pharm Exec Profiles Five Recent Drug Launches
Serial Problem Solver
Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.
Adding More Context to Biotech Headwinds
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
The Comeback of Unbranded Campaigns
Vaccines spotlight recent resurgence of useful messaging tool.
Driving Digital Progress in Medical Affairs
Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.
More Jobs and Less Talent Has Created an Imbalance in Pharma
If not addressed, effects could impact innovation, diversity.
Advanced Therapy Makers Claim a Double Barrier Over Access
Treatment availability for rare disease patients under fire in Europe.
FDA Advances New Drugs, Biosimilars
But accelerated approval program faces scrutiny.
Pharm Exec at 40 (2007–2010)
Looking Back at 2007–2010.
Pharma Campaigns Take Center Stage
Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.
Startup Launch Guide: Avoiding 10 Common Pain Points
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
